Haemorrhagic gastritis and bleeding following rofecoxib administration.
Tuccori
M
M
Martini
G
G
Giustini
S E
SE
Salvetti
A
A
Blandizzi
C
C
Del Tacca
M
M
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000368:Aged; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects*; D005260:Female; D005756:Gastritis / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D006471:Gastrointestinal Hemorrhage / Q000188:drug therapy / Q000209:etiology*; D005773:Gastroscopy; D006801:Humans; D007783:Lactones / Q000009:adverse effects*; D064747:Lansoprazole; D009853:Omeprazole / Q000031:analogs & derivatives / Q000627:therapeutic use; D010003:Osteoarthritis / Q000188:drug therapy; D013450:Sulfones / Q000009:adverse effects*; D016896:Treatment Outcome
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D013450:Sulfones; D064747:Lansoprazole; C116926:rofecoxib; D009853:Omeprazole